Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions

Drug Metabolism Letters

Volumn 10, Issue 1, 2016, Pages 38-48

  Namour, Florence ^a   Desrivot, Julie ^a   Van der Aa, Annegret ^b   Harrison, Pille ^b   Tasset, Chantal ^b   van’t Klooster, Gerben ^b  

^a Galapagos SASU   (France)

^b GALAPAGOS NV   (Belgium)

Author keywords

Carboxylesterases; CYP450; Drug transporters; Drug drug interaction; Filgotinib; Selective JAK1

Indexed keywords

BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; CYTOCHROME P450; CYTOCHROME P450 INDUCER; CYTOCHROME P450 INHIBITOR; DIGOXIN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FILGOTINIB; GLUCURONOSYLTRANSFERASE; JANUS KINASE INHIBITOR; METHOTREXATE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PHENOBARBITAL; PLACEBO; PRAZOSIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TAUROCHOLIC ACID; ANTIRHEUMATIC AGENT; CARRIER PROTEIN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; TRIAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; CHO CELL LINE; CLINICAL TRIAL; CRICETULUS; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; RISK ASSESSMENT;

ADULT; ANIMALS; ANTIRHEUMATIC AGENTS; BIOTRANSFORMATION; CHO CELLS; CRICETULUS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; JANUS KINASE 1; MALE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MICROSOMES, LIVER; MIDAZOLAM; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; RECOMBINANT PROTEINS; RISK ASSESSMENT; SUBSTRATE SPECIFICITY; TRANSFECTION; TRIAZOLES;

EID: 84959923183     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312810666151223103353     Document Type: Article

References (24)

1. Haan, C.; Rolvering, C.; Raulf, F.; Kapp, M.; Druckes, P.; Thoma, G.; Behrmann, I.; Zerwes, H. Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc Containing Cytokine Receptors. Chem. Biol., 2011, 18, 314-323.
2. Van Rompaey, L.; Galien, R.; Van der Aar, E.; Clement-Lacroix, P.; Nelles, L.; Smets, B.; Lepescheux, L.; Christophe, T.; Conrath, K.; Vandeghinste, N.; Vayssiere, B.; De Vos, S.; Fletcher, S.; Brys, R.; Van 't Klooster, G.; Feyen, J.; Menet, C. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1 for the treatment of inflammatory diseases. J. Immunol., 2013, 191(7), 3568-3577.
3. Galien, R.; Vayssiere, B.; De Vos, S.; Auberval, M.; Vandeghinste, N.; Dupont, S.; Clement-Lacroix, P.; Delerive, P.; Vanhoutte, F.; Brys, R.; Van der Aa, A.; Van Rompaey, L.; Van't Klooster, G. In: Analyis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy subjects and rheumatoid arthritis patients. Annual Congress of Rheumatology (ACR), San Diego, US, October 25-30, 2013; 478.
4. Namour, F.; Diderichsen, P. M.; Cox, E.; Vayssiere, B.; Van der Aa, A.; Tasset, C. Van't Klooster, G. Pharmacokinetis and pharmacokinetics/pharmacodynamics of filgotinib (GLPG0634) a selective JAK1 inhibitor, in support of Phase 2B dose selection. Clin. Pharmacokinet., 2015, 54(8), 859-874.
5. Delafuente J. C. Understanding and preventing drug interactions in elderly patients. Crit. Rev. Oncol. Hematol., 2003, 48, 133-143.
6. Lai, Y.; Hsiao, P. Beyond the ITC White Paper: emerging sciences in drug transporters and opportunities for drug development. Curr. Pharm. Des., 2014, 20(10), 1577-1594.
7. Guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing and labelling recommendation, US. Food and Drug Administration, February 2012.
8. Guideline on the investigation of drug interactions. EMA guideline, June 2012.
9. Imai, T.; Ohura, K. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr. Drug Metab., 2010, 11, 793-805.
10. Gripon, P.; Rumin, S.; Urban, S.; Le Seyec, J.; Glaise, D.; Cannie, I.; Guyomard, C.; Lucas, J.; Trepo, C.; Guguen-Guillouzo, C. Infection of a hepatome cell line by hepatitis virus. PNAS, 2002, 99, 15666-15660.
11. Animat, C.; Piton, A.; Glaise, D.; Le Charpentier, T.; Langouet, S.; Morel, F.; Guguen-Guillouzo, C.; Guillouzo, A. Expression of cytochromes P450, conjugating enzymes and nuclear receptor in human hepatoma hepaRG cells. Drug Metab. Dispos., 2006, 34, 75-83.
12. Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Firsher, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; NI, L.; Kumar, G.; McLeod, J.; Obacj, R. S.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 2003, 31, 815-832.
13. Diletti, E.; Hauschke, D.; Steinijans, V. W. Sample size determinations for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol., 1991, 29(1), 1-8.
14. Lown, K. S.; Thummel, K. E.; Benedict, P. E.; Shen D. D.; Turgeon, D. K.; Berent, S.; Watkins, P. B. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther., 1995, 57(1), 16-24.
15. Mazur, M.; Voloshyn, O.; Stanislavchuk, M.; Van der Aa, A.; Namour, F.; Galien, R.; Meuleners, L.; Van 't Klooster, G.; Vanhoutte, F. Efficacy, safety, pharmacokinetics and pharmacodynamics of filgotinib, a selective Janus kinase 1 inhibitor, after short-term treatment of rheumatoid arthritis; results of two Phase IIA trial; data on file.
16. Imai, T.; Taketani, M.; Shii, M.; Hosokawa, M.; Chiba, K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos. 2006, 34, 1734-1741.
17. Taketami, M.; Shii, M.; Ohura, K.; Ninomiya, S.; Imai, T. Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., 2007, 81, 924-932.
18. Hosokawa, M. structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules, 2008, 13, 412-431.
19. Williams, T. E.; Bacon, J. A.; Bender, D. M.; Lowinger, J. J.; Guo, W.; Ehsani, M. E.; Wang, X.; Wang, H.; Qian, Y.; Ruterbories, K. J.; Wrighton, S. A.; Perkins, E. J. Characterization of the expression and activity of carboxylesterases 1 and 2 from the Beagle dog, Cynomolgus monkey and human. Drug Metab. Dispos., 2011, 39(12), 2305-2313.
20. Vanhoutte F., Galien R., Namour F., Van der Aa A., Vayssiere B., Blockhuys S., Brys R. van't Klooster. Safety, tolerability, pharmacokinetics and pharmacodynamics of the selective JAK1 inhibitor filgotinib, given to healthy subjects; in preparation.
21. Backman, J. T.; Kyrklund, C.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther., 2002, 72(6), 685-691.
22. Niemi, N.; Backman, J. T.; Granfors, M.; Laitila, J.; Neuvonen, M.; Neuvonen, P. J. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, 46, 1319-1323.
23. Ogilvie, B. W.; Zhang, D.; Li, W.; Rodrigues, A. D.; Gipson, A. E.; Holsapple, J.; Toren, P.; Parkinson, A. Glucuronidation converts gemfibrozil to a potent metabolism dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos., 2006, 34, 191-197.
24. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada, M.; Cha, S. H.; Sekine, T.; Endou, H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther., 2002, 302, 666-671.